Literature DB >> 1369991

Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases.

T W Chang1, F M Davis, N C Sun, C R Sun, D W MacGlashan, R G Hamilton.   

Abstract

Monoclonal antibodies (MAbs) specific for surface antigens of lymphocytes are being used to target and deplete tumorous or normal lymphocytes in vivo. Here, we report evidence for the existence of antigenic epitopes on IgE that are accessible on IgE-secreting B cells but not on other cells bearing IgE. Among 42 murine MAbs specific for human IgE, two were shown by fluorescence flow cytometric analyses to bind to IgE-secreting cell lines but not to IgE bound to high-affinity IgE.Fc receptors (Fc epsilon RI) on basophils or low-affinity IgE receptors (Fc epsilon RII) on other cell types. Neither could they induce histamine release from basophils of various donors even under very permissive conditions. These antibodies may be useful for targeting IgE-secreting B cells in patients suffering from IgE-mediated allergies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1369991     DOI: 10.1038/nbt0290-122

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  14 in total

1.  Recombinant soluble form of the human high-affinity immunoglobulin E (IgE) receptor inhibits IgE production through its specific binding to IgE-bearing B cells.

Authors:  Y Yanagihara; K Kajiwara; K Ikizawa; T Koshio; K Okumura; C Ra
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 2.  IgE-dependent signaling as a therapeutic target for allergies.

Authors:  Donald W MacGlashan
Journal:  Trends Pharmacol Sci       Date:  2012-06-30       Impact factor: 14.819

3.  The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.

Authors:  Bianca Balbino; Pauline Herviou; Ophélie Godon; Julien Stackowicz; Odile Richard-Le Goff; Bruno Iannascoli; Delphine Sterlin; Sébastien Brûlé; Gael A Millot; Faith M Harris; Vera A Voronina; Kari C Nadeau; Lynn E Macdonald; Andrew J Murphy; Pierre Bruhns; Laurent L Reber
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 4.  Can anti-IgE be used to treat allergy?

Authors:  F M Davis; L A Gossett; K L Pinkston; R S Liou; L K Sun; Y W Kim; N T Chang; T W Chang; K Wagner; J Bews
Journal:  Springer Semin Immunopathol       Date:  1993

Review 5.  Novel approaches in immunotherapy.

Authors:  J M Saint-Remy
Journal:  Clin Rev Allergy       Date:  1994

Review 6.  From IgE to Omalizumab.

Authors:  Toshiaki Kawakami; Ulrich Blank
Journal:  J Immunol       Date:  2016-12-01       Impact factor: 5.422

Review 7.  Cowpea mosaic virus as a vaccine carrier of heterologous antigens.

Authors:  F R Brennan; T D Jones; W D Hamilton
Journal:  Mol Biotechnol       Date:  2001-01       Impact factor: 2.695

Review 8.  Past, present, and future of anti-IgE biologics.

Authors:  Pascal Guntern; Alexander Eggel
Journal:  Allergy       Date:  2020-04-21       Impact factor: 13.146

Review 9.  Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.

Authors:  Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern
Journal:  Allergy       Date:  2021-09-15       Impact factor: 14.710

Review 10.  Oral immunotherapy for food allergy.

Authors:  Deborah M Hussey Freeland; Monali Manohar; Sandra Andorf; Benjamin D Hobson; Wenming Zhang; Kari C Nadeau
Journal:  Semin Immunol       Date:  2017-08-31       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.